Literature DB >> 10326868

Loss of HNF1alpha function in human renal cell carcinoma: frequent mutations in the VHL gene but not the HNF1alpha gene.

I Lemm1, A Lingott, E Pogge v Strandmann, C Zoidl, M P Bulman, A T Hattersley, W A Schulz, T Ebert, G U Ryffel.   

Abstract

Human renal cell carcinoma (RCC) is a common malignant disease of the kidney characterized by dedifferentiation of renal epithelial cells. Our previous experiments showed that most RCCs have a loss of function of the tissue-specific transcription factor hepatocyte nuclear factor (HNF) 1alpha. Detailed analyses of the 10 exons encoding HNF1alpha in 32 human RCCs by single-strand conformation polymorphism analysis and direct DNA sequencing revealed no tumor-associated mutation, whereas with the same probes we frequently found mutations in the von Hippel-Lindau tumor suppressor gene. No mutation leading to loss of HNF1alpha function was detected by analyzing the integrity of the HNF1alpha transcripts in the RNA derived from RCCs by the protein truncation test. Investigating human RCC cell lines by western blotting and gel retardation assays showed a dramatic loss in the expression of the tissue-specific transcription factor HNF1alpha in eight of 10 cell lines. As the HNF1alpha-related transcription factor HNF1beta was expressed in all these tumor cell lines, the loss of HNF1alpha expression was a specific event and was maintained in RCC cell lines. The loss of HNF1alpha expression in RCC cell lines on the RNA level was confirmed by reverse transcription polymerase chain reaction. We propose that tumor-associated mutations in the HNF1alpha gene do not occur in human RCC and that the loss of function is partially due to a transcriptional inactivation of the HNF1alpha gene.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10326868

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  7 in total

1.  VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling.

Authors:  E J Davidowitz; A R Schoenfeld; R D Burk
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

2.  Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma.

Authors:  Alison C Young; Rachel A Craven; Dena Cohen; Claire Taylor; Christopher Booth; Patricia Harnden; David A Cairns; Dewi Astuti; Walter Gregory; Eamonn R Maher; Margaret A Knowles; Adrian Joyce; Peter J Selby; Rosamonde E Banks
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

3.  The mutated human gene encoding hepatocyte nuclear factor 1beta inhibits kidney formation in developing Xenopus embryos.

Authors:  W Wild; E Pogge von Strandmann; A Nastos; S Senkel; A Lingott-Frieg; M Bulman; C Bingham; S Ellard; A T Hattersley; G U Ryffel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

4.  Phenotype reversion in fetal human liver epithelial cells identifies the role of an intermediate meso-endodermal stage before hepatic maturation.

Authors:  Mari Inada; Antonia Follenzi; Kang Cheng; Manju Surana; Brigid Joseph; Daniel Benten; Sriram Bandi; Hong Qian; Sanjeev Gupta
Journal:  J Cell Sci       Date:  2008-03-04       Impact factor: 5.285

5.  Hepatocyte nuclear factor 1A (HNF1A) as a possible tumor suppressor in pancreatic cancer.

Authors:  Zhaofan Luo; Yanan Li; Huamin Wang; Jason Fleming; Min Li; Yaan Kang; Ran Zhang; Donghui Li
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

6.  Renal oncometabolite L-2-hydroxyglutarate imposes a block in kidney tubulogenesis: Evidence for an epigenetic basis for the L-2HG-induced impairment of differentiation.

Authors:  Mary Taub; Nader H Mahmoudzadeh; Jason M Tennessen; Sunil Sudarshan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-05       Impact factor: 6.055

7.  Epigenetic inactivation of TCF2 in ovarian cancer and various cancer cell lines.

Authors:  K Terasawa; M Toyota; S Sagae; K Ogi; H Suzuki; T Sonoda; K Akino; R Maruyama; N Nishikawa; K Imai; Y Shinomura; T Saito; T Tokino
Journal:  Br J Cancer       Date:  2006-03-27       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.